Sana Biotechnology reported a GAAP net income for the third quarter of 2026, primarily driven by significant non-cash gains rather than operational revenue. The company maintains a sufficient cash runway to reach critical clinical milestones for its lead hypoimmune platform candidates, including the anticipated clinical entry of SC451.
Key Highlights
- GAAP EPS of $0.07 beat the estimated loss of $0.15, though results were inflated by a $63.4 million non-cash gain related to the fair value adjustment of success payment liabilities and contingent consideration.
- Cash, cash equivalents, and marketable securities stood at $121.7 million as of September 30, 2026, with management projecting a cash runway into mid-2027.
- The company is on track to file an Investigational New Drug (IND) application and initiate a Phase 1/2 trial for SC451 in type 1 diabetes by the end of 2026.
- Clinical study initiation for SG293 in non-Hodgkin lymphoma remains scheduled for the first quarter of 2027, with proof-of-concept data expected later that year.